Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
QIMC Extends DDH-26-05 Drilling to Beyond 1,000 Metres and Launches In-Situ Hydrogen Characterization and Extraction Program at Bennett Hill as Seismic Further Corroborates Two Distinct Hydrogen Systems in Nova Scotia
